Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

1. Written informed assent and parental permission (age as per local law) obtained at
screening before any assessment is performed.

2. Must be 6 to less than 18 years of age at the time of randomization

3. Moderate to Severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011
score of ≥ 3, and BSA involvement of ≥10%, at randomization.

4. Subject being regarded by the investigator to be a candidate for systemic therapy.

Exclusion Criteria:

1. Forms of psoriasis other than chronic plaque-type active at randomization

2. Drug-induced psoriasis

3. Ongoing use of prohibited treatments

4. Female subjects of childbearing potential defined as all women physiologically capable
of becoming pregnant, unless they are using effective methods of contraception during
dosing and for 16 weeks after stopping study treatment

5. Pregnant or nursing (lactating) females

6. Subjects with total WBC count <2,500/μL, or platelets <100,000/μL or neutrophils
<1,500/μL or hemoglobin <8.5 g/dL at screening

7. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17
or the IL-17 receptor